Adrenocortical Carcinoma: Difference between revisions
From OncoWiki
Jump to navigationJump to search
(Created page with "=Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy=") |
|||
| Line 1: | Line 1: | ||
=Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy= | =Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy= | ||
==Mitotane (Lysodren)== | |||
'''There is limited and controversial clinical trial information about adjuvant mitotane use. See the references for additional case series and expert recommendation articles.''' | |||
===Regimen #1, Wängberg et al. 2010=== | |||
Level of Evidence: | |||
<span | |||
style="background:#EEEE00; | |||
padding:3px 6px 3px 6px; | |||
border-color:black; | |||
border-width:2px; | |||
border-style:solid;">Phase II</span> | |||
''Patients started on adjuvant mitotane within 4 weeks of their surgical resection.'' | |||
*[[Mitotane (Lysodren)]] 2000 mg PO per day (frequency not specified, such as whether the total daily dose was divided into a few doses throughout the day); within the first 2 to 3 months, [[Mitotane (Lysodren)]] dose was adjusted to achieve a target therapeutic drug level of 14 to 20 mg/L | |||
'''2 to 3-year course''' | |||
Revision as of 02:43, 30 October 2013
Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy
Mitotane (Lysodren)
There is limited and controversial clinical trial information about adjuvant mitotane use. See the references for additional case series and expert recommendation articles.
Regimen #1, Wängberg et al. 2010
Level of Evidence: Phase II
Patients started on adjuvant mitotane within 4 weeks of their surgical resection.
- Mitotane (Lysodren) 2000 mg PO per day (frequency not specified, such as whether the total daily dose was divided into a few doses throughout the day); within the first 2 to 3 months, Mitotane (Lysodren) dose was adjusted to achieve a target therapeutic drug level of 14 to 20 mg/L
2 to 3-year course
